Royalty Report: Drugs, Drug Discovery, Disease – Collection: 300741

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Drug Discovery
  • Disease
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 300741

License Grant
Licensor grants an exclusive license, including the right to sublicense, under the Licensor Patents, to make, use, offer for sale, sell and import Licensed Products worldwide.

Licensor grants an exclusive license, including the right to sublicense, under Licensors rights in the Licensor Technology, to use, copy, distribute and create derivative works of Licensor Technology to make, use, offer for sale, sell and import Licensed Products worldwide.

This agreement includes non-exclusive grants back from Licensee.

License Property
The Patent s include Morphinan Compounds, and, Combination of Morphinan Compounds Antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury.

D-DM means any compound having the structure of dextromethorphan, or a salt, solvate, or hydrate thereof, wherein for a given sample of the compound, the abundance of deuterium at one or more of the hydrogens of dextromethorphan is greater than the natural abundance of deuterium.  The term D-DM also includes dextromethorphan metabolites.

D-DM Analog means any compound wherein R I is hydrocarbyl of one to four carbons or -O-R2 wherein R2 is -CH2F, CHF2, CF3 or hydrocarbyl of two to four Carbons or a salt, solvate or hydrate thereof wherein for a given sample of the compound  the abundance of deuterium at one or more of the hydrogens of the structure, including any of the hydrogens of the aforementioned hydrocarbyl of one to four carbons, -CH2F, -CHF2, hydrocarbyl of two to four carbons, or any of the hydrogens of the depicted N-methyl is greater than the natural abundance of deuterium.  The term D-DM analog also includes metabolites of any compound having the structure described.

D-DM and Quinidine Product means a Licensed Product that contains or is administered with quinidine in accordance with the approved label for such Licensed Product.

D-DM Only Product means a Licensed Product that is not a D-DM and Quinidine Product.

Deuterated Products means a compound, wherein for a given sample of the compound, the abundance of deuterium at one or more of the hydrogens of the compound is greater than the natural abundance of deuterium.

Field of Use
The field of use is for treatment of a Restricted Indication.  Restricted Indication means pseudobulbar affect (also known as emotional lability in some regulatory jurisdictions), or behavioral symptoms in dementia patients.

IPSCIO Record ID: 280835

License Grant
Licensor grants Licensee an exclusive, sublicense under the Patents and license under the Know-How and Licensor Improvements to offer, make, have made, use, lease, export, import, sell and resell Products, use the Process or both in the Territory.
License Property
Licensor has developed certain additional technology and know-how related to the patents, patent applications and the medical use of dextromethorphan or a combination of dextromethorphan with quinidine or other enzyme inhibitors.

United States Patent Number 5,166,207, 'Method for Enhancing the Systemic Delivery of Dextromethorphan for the Treatment of Neurological Disorders'

United States Patent Number 5,166,207, 'Method for Enhancing the Systemic Delivery of Dextromethorphan for the Treatment of Neurological Disorders'

United States Patent Number 5,350,756, 'Use of a Cytochrome Oxidase Inhibitor to Increase the Cough-Suppressing Activity of Dextromethorphan'

United States Patent Number 5,366,980, 'Use of extromethorphan and an Oxidase Inhibitor to Treat Dermatitis'

United States Patent Number 5,863,927, 'Dextromethorphan and an Oxidase Inhibitor for Treating Intractable Conditions'

PCT Application PCT/US94/10771, 'Compositions Useful for the
Preparation of Medicines for Treating a Variety of Intractable Disorders'

United States Patent Application Number 09/471,060, filed December 22, 1999, entitled 'Dextromethorphan and Oxidase Inhibitor for Weaning Patients from Narcotics and Anti-Depressants'

Field of Use
Dextromethorphan or DM, is a well-known NMDA receptor antagonist. It has been reported in medical literature that DM is effective in reducing pain associated with diabetic neuropathy.

(i) EMOTIONAL LABILITY INDICATION.
(ii) CHRONIC PAIN INDICATION.
(iii) CHRONIC COUGH INDICATION.
(iv) DERMATITIS INDICATION.
(v) PRODUCTS FOR WEANING PATIENTS FROM NARCOTICS AND ANTI-DEPRESSANTS.

Emotional lability refers to rapid, often exaggerated changes in mood, where strong emotions or feelings (uncontrollable laughing or crying, or heightened irritability or temper) occur.

Dermatitis, also known as eczema, is a group of diseases that result in inflammation of the skin.

IPSCIO Record ID: 372521

License Grant
Licensor grants to Licensee of Germany, an exclusive right and license under the Licensor Patent Rights, the Licensor Know-How and Licensors interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold PET Ligand and Products in the Field in the Territory.

Licensee has the right to develop and commercialize the PET Ligand as set forth.

License Property
Licensor has discovered proprietary compounds of the NMDA class and possesses proprietary intellectual property rights relating thereto, including the Licensor Patent Rights.

Licensor patents and technology relate to Imidazole Derivatives.  The invention relates to novel Imidazole Derivatives which are NMDA receptor subtype specific blockers, useful in the treatment of acute forms of neurodegeneration (stroke, brain trauma) and  of chronic forms of neurodegeneration ( Alzheimers disease, Parkinson, Huntingtons disease, ALS).

The products covered by the License Agreement are xO0678867; xO0693960; xO4378536; xO4394127; xO0631908; and, xO0717626.

The term Compound shall mean any of xO-0631908, xO-0678867, xO-0693960, xO4378536, x0-4394127, xO-0717626 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed to the Agreement, including their salts, polymorphs, crystal forms, esters, hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers.

The term EVT 101 shall mean xO-4394127.

The term EVT 103 shall mean xO-0717626.

The term PET Ligand shall mean a Compound, with the exception of EVT 101 and EVT 103,
appropriately labelled for use in positron emission tomography for the specific labelling of NMDA NR2B subunit containing receptors in vivo.

Field of Use
The patent portfolio covers NMDA receptor NR2B subtype selective antagonists (the
EVT 100 family) for the treatment of a variety of CNS disorders such as Alzheimer’s disease, neuropathic pain and Parkinson’s Disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.